Last reviewed · How we verify
Autologous Fecal Microbiota Transplantation — Competitive Intelligence Brief
phase 2
Gastroenterology
Small molecule
Live · refreshed every 30 min
Target snapshot
Autologous Fecal Microbiota Transplantation (Autologous Fecal Microbiota Transplantation) — MaaT Pharma. Autologous Fecal Microbiota Transplantation involves transplanting a patient's own fecal microbiota to restore a balanced gut microbiome.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Autologous Fecal Microbiota Transplantation TARGET | Autologous Fecal Microbiota Transplantation | MaaT Pharma | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Autologous Fecal Microbiota Transplantation CI watch — RSS
- Autologous Fecal Microbiota Transplantation CI watch — Atom
- Autologous Fecal Microbiota Transplantation CI watch — JSON
- Autologous Fecal Microbiota Transplantation alone — RSS
Cite this brief
Drug Landscape (2026). Autologous Fecal Microbiota Transplantation — Competitive Intelligence Brief. https://druglandscape.com/ci/autologous-fecal-microbiota-transplantation. Accessed 2026-05-18.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab